SEC Filings
Tonix Lawsuit Triggers Up To 30 Months Of Delay For Generic TONMYA Approval
Tonix seeks to keep the competing drug’s approval from taking effect until the last asserted patent expires.
Tonix Pharmaceuticals (TNXP) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Tonix seeks to keep the competing drug’s approval from taking effect until the last asserted patent expires.
Earnings
Management says core patents protect TONMYA into 2034 and describes successor research as small beside its depression trial.
SEC Filings
Insurance access expanded, while commercialization and research spending climbed and operating cash use increased.
Earnings
The company also put its September 30 cash at about $162.8 million, in unaudited figures it says could change.